Skip to main content

Croda, Novasep part of key COVID vaccines

18th November 2020

Submitted by:

Andrew Warmington

Both Croda International and Novasep are involved in some of the vaccines nearing approval for use in the treatment of COVID-19 it has emerged. This follows on from many other announcements of development agreements involving other fine chemical companies earlier in the year.

Via its newly acquired subsidiary, Avanti Polar Lipids, Croda has agreed to supply novel excipients used in the manufacture of Pfizer’s mRNA COVID-19 vaccine candidate, for which 90% effectiveness has been claimed in human tests. The five-year deal includes an initial supply contract for four component excipients for the first three years.

Croda said that it had been working with Avanti before and since the acquisition “to refine the complex processes involved in achieving the volumes of high-purity excipients required by its pharmaceutical customers”. It has reprioritised investment, resources and other projects over the last few months to focus on the delivery of this project.

Meanwhile, Novasep has signed a multi-year master supply and development agreement with AstraZeneca to support large-scale production of the active substance of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222. This follows an initial agreement signed in June. Novasep will produce the active substance at its site in Seneffe, Belgium. The company expects to increase its workforce from 280 to close to 400 by 2021 to support this project. The project is also supported by the Inclusive Alliance for Vaccines, comprising France, Germany, Italy and the Netherlands.

Another candidate that has moved closer to fruition following highly promising interim Phase III clinical trial data is that developed by Moderna’s mRNA-1273. Nearly 95% effectiveness has been claimed for it in recent trials. Under a ten-year strategic collaboration agreement that was agreed in May, Lonza is carrying out large-scale manufacture at Portsmouth, New Hampshire, and expects to begin production at its main site in Visp, Switzerland, by 2021. This will amount to 400 million doses/year. CordenPharma is supplying the lipid excipients.

During the summer, Sterling Pharma Solutions agreed to carry out final purification of drug product for Moleculin Biotech’s WP1122 drug candidate from its site in Cary, North Carolina; while, Novavax reached separate agreements with Fujifilm Diosynth Biotechnologies and AGC Biologics to manufacture the drug bulk substance and the saponin-based Matrix-M adjuvant respectively for its COVID-19 vaccine candidate, NVX-CoV2373.

In addition, AMRI was named as the second US API supplier for ViralClear Pharmaceuticals, which is investigating the potential of merimepodib to fight COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators. Merimepodib was previously developed for chronic hepatitis C and psoriasis by Vertex.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington